• About
• Links
• Contact
• Sitemap

RNA Interference Markets

Since its discovery, the naturally occurring RNA (ribonucleic acid) interference effect has been acclaimed as the most exciting technical breakthrough in biological research in the last decade. Some industry analysts predict that RNA interference (RNAi) may even surpass PCR as a top technology.

RNAi allows scientists to silence the expression or effect of a gene under study. This is known as gene knockdown. This field has rapidly emerged as a fast-growing new market.

The purpose of this report is to review the market for RNAi testing equipment and supplies.

RNAi is a mechanism in molecular biology where the presence of certain fragments of double-stranded RNA (dsRNA) interferes with the expression of a particular gene which shares a similar sequence with the dsRNA. This study defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence market size and growth for RNAi testing.

The main objectives of this study are to:

1) understand the different sectors of RNAi testing market and to look at a description of the instruments, reagents and supplies marketed by major companies in each segment;

2) obtain a complete understanding of the individual RNAi-testing platforms-from basic principles to clinical applications;

3) discover feasible market opportunities by identifying high-growth applications in different analytical diagnostic areas, with a focus on the biggest and expanding markets;

4) focus on global industry developments and trends through an in-depth analysis of the major world markets for RNAi measurement technology, including growth forecasts; and

5) present market figures related to the current value of RNAi testing, market projections, market share, key players and sector growth rates.

 

Table of Contents

• 1.Overview5
  • 1.1Objectives5
  • 1.2Scope5
  • 1.3Methodology7
  • 1.4Executive Summary8
  
  
• 2.RNA Interference (RNAi)11
  • 2.1Introduction11
  • 2.2Overview of RNA Interference11
    • 2.2.1Classes of Endogenous Small RNAs: siRNA, rasiRNA and miRNA12
    • 2.2.2Mechanism of RNAi In Vivo13
  • 2.3Glossary16
  • 2.4What Areas of Research Does RNAi Impact?17
    • 2.4.1RNAi Technology in Life Sciences Research, Drug Discovery and Development18
      • 2.4.1.1Clinical Trials Featuring RNAi-based Therapeutics20
    • 2.4.2RNAi Technology in Agriculture24
      • 2.4.2.1Companies Utilizing RNAi Technology for Agriculture25
      
      
• 3.Technology Trends in RNAi Space27
  • 3.1Overview27
  • 3.2End-User Segmentation27
  • 3.3Technologies for Inducing RNAi28
    • 3.3.1Methods for Detecting Gene Silencing29
    • 3.3.2Libraries of siRNAs/shRNAs to Knockdown Genes En Masse30
      • 3.3.2.1Publicly Available Large-scale Mammalian RNAi Libraries31
      • 3.3.2.2The RNAi Consortium (TRC)32
      • 3.3.2.3RNAi-related Consortia Based in Europe34
    • 3.3.3Comparison of Strategies for Target Validation36
      • 3.3.3.1Market Shifts in RNAi Space: Where Is It Headed?36
      • 3.3.3.2Intellectual Property and Patent Issues37
      • 3.3.3.3Funding in RNAi Space: Grants, Venture Capital and IPOs39
      • 3.3.3.4Partnerships, Alliances, Mergers and Acquisitions41
    • 3.3.4miRNA-Based RNAi: Leading Edge of RNAi Space43
      • 3.3.4.1Biological Function of miRNAs43
      • 3.3.4.2Role of miRNAs in Disease44
      
      
• 4.RNAi Market Analysis54
  • 4.1Overview54
  • 4.2Market Data Collection and Respondent Pool54
    • 4.2.1Respondent Pool Characteristics55
  • 4.3RNAi Technologies/Products in Research Applications57
  • 4.4RNAi Technologies/Products: Market Shares (Quantitative)57
  • 4.5Quantitative Metrics of RNAi Usage: Market Opportunity and Growth60
    • 4.5.1Growth of Various Segments in RNAi Space62
    • 4.5.2Product Formats and Representation in RNAi Marketplace63
  • 4.6RNAi Marketplace: Challenges, Unmet Needs and Drivers69
    • 4.6.1Unmet Needs in RNAi Space70
    • 4.6.2RNAi Market: Qualitative Growth Drivers72
    
    
• 5.The RNAi Landscape73
  • 5.1Overview73
  • 5.2Market Segmentation of RNAi and Segment Characteristics73
  • 5.3Quantitative Market Opportunities in RNAi Space75
    • 5.3.1Opportunities in miRNA Space75
    • 5.3.2Opportunities in siRNA/shRNA Space77
  • 5.4RNAi Product Offerings and Associated Business Models78
  
  
• 6.Company Profiles81
  • 6.1Alfacell Corporation82
  • 6.2Allele Biotechnology and Pharmaceuticals, Inc.82
  • 6.3Alnylam Pharmaceuticals82
  • 6.4Ambion84
  • 6.5Applied Biosystems Group84
  • 6.6Asuragen, Inc.85
  • 6.7Avalon Pharmaceuticals, Inc.85
  • 6.8B-Bridge International, Inc.85
  • 6.9Bio-Rad Laboratories86
  • 6.10Calando Pharmaceuticals, Inc.86
  • 6.11Cepheid87
  • 6.12Cequent87
  • 6.13Clontech Laboratories, Inc.87
  • 6.14CombiMatrix Corporation88
  • 6.15Cyntellect, Inc.88
  • 6.16CytRx Corp.88
  • 6.17Dharmacon89
  • 6.18Dicerna90
  • 6.19Galenea Corporation90
  • 6.20GeneCopoeia, Inc.90
  • 6.21GeneThera, Inc.91
  • 6.22Genlantis91
  • 6.23GenoSensor91
  • 6.24GRL, Inc.91
  • 6.25IDT92
  • 6.26Imgenex Corporation92
  • 6.27Ingenuity Systems92
  • 6.28Isis Pharmaceuticals, LLC92
  • 6.29Intradigm Corporation94
  • 6.30Invitrogen94
  • 6.31 InvivoGen95
  • 6.32LC Sciences95
  • 6.33Lentigen Corporation95
  • 6.34Merck & Co., Inc.95
  • 6.35Mirus Bio Corporation96
  • 6.36Monsanto96
  • 6.37Nastech Pharmaceutical Company, Inc.96
  • 6.38New England BioLabs97
  • 6.39Nucleonics, Inc.97
  • 6.40Open Biosystems, Inc.97
  • 6.41OPKO Health, Inc.98
  • 6.42OriGene98
  • 6.43Panomics, Inc.99
  • 6.44PhaseRx99
  • 6.45Promega Corp.99
  • 6.46Quark Pharmaceuticals, Inc.99
  • 6.47RXi Pharmaceuticals Corporation100
  • 6.48Senetek PLC100
  • 6.49Sigma-Aldrich100
  • 6.50Sirna Therapeutics101
  • 6.51Sirnaomics, Inc.101
  • 6.52SomaGenics, Inc.102
  • 6.53System Biosciences103
  • 6.54Tacere Therapeutics103
  • 6.55Targeted Genetics Corporation104
  • 6.56Third Wave Technologies104
  • 6.57Traversa104
  • 6.58Actigenics SA105
  • 6.59Amaxa105
  • 6.60AstraZeneca PLC106
  • 6.61Cenix Bioscience GmbH106
  • 6.62deVGen N.V.107
  • 6.63DNAVision107
  • 6.64Exiqon107
  • 6.65Genovis108
  • 6.66genOway108
  • 6.67imaGenes GmbH108
  • 6.68MWG Biotech AG109
  • 6.69OZ Biosciences109
  • 6.70Prosensa Holding109
  • 6.71QIAGEN110
  • 6.72RNAx GmbH (Germany)111
  • 6.73Roche112
  • 6.74Rosetta Genomics, Ltd.113
  • 6.75Santaris Pharma A/S113
  • 6.76Silence Therapeutics PLC114
  • 6.77TaconicArtemis GmbH114
  • 6.78TRANSAT114
  • 6.79alphaGEN Co., Ltd.115
  • 6.80Benitec, Ltd.116
  • 6.81Bioneer116
  • 6.82CytoPathfinder, Inc.116
  • 6.83Genesis Research & Development Corp.117
  • 6.84GeneDesign, Inc.117
  • 6.85GNI Pharmaceutical Corporation117
  • 6.86Koken Co., Ltd.118
  • 6.87NanoCarrier Co., Ltd.118
  • 6.88Oncolys Biopharma, Inc.118
  • 6.89RealGene Bio-Technologies, Inc.118
  • 6.90Samchully Pharmaceuticals118
  • 6.91Samyang Corp.119
  • 6.92Shanghai Biochip119
  • 6.93Shanghai GenePharma Co.119
  • 6.94Shanghai Genomics, Inc.120
  • 6.95Transgene Biotek, Ltd.120
  • 6.96Tekmira121
  
  
  

 

INDEX OF TABLES

Table 2.1: Advantages/Disadvantages of siRNAs and shRNAs as Inducers of RNAi in Mammalian Cells18

Table 2.2: Prevalence of siRNA-mediated RNAi in Disease Models, as Reported in Scientific Literature20

Table 2.3: RNAi-based Therapeutics in Clinical Trials21

Table 2.4: Suppliers of Enabling Technologies and Tools in RNAi Space22

Table 2.5: Suppliers of siRNA/shRNA Products (by Product/Service Class)23

Table 3.1: Currently Utilized Technologies for Inducing RNAi-Mediated Knockdown29

Table 3.2: Comparison of mRNA Detection Technologies29

Table 3.3: Characteristics of Various Publicly available Mouse and Human RNAi Libraries31

Table 3.4: Comparison of Formats for Library-Based Gene Knockdown33

Table 3.5: Strategies for Target Validation by Pharma/Biotech: RNAi and Others36

Table 3.6: Seminal Patents in RNAi39

Table 3.7: Venture Capital Raised by Selected Companies in the RNAi Space40

Table 3.8: List of Public Biotech Companies in RNAi Space41

Table 3.9: Disease-Related miRNAs48

Table 3.10: Publicly Available Computational Programs for Identifying miRNA Sequences/Targets49

Table 3.11: SWOT Analysis of siRNA Oligonucleotides52

Table 3.12: Transfection Reagents (Lipid-Mediated Delivery)52

Table 3.13: shRNA Plasmid Constructs53

Table 3.14: shRNA Pooled Libraries or Arrayed Collections (Retroviral/Lentiviral Delivery)53

Table 5.1: RNAi Market Segmentation and Research Settings73

Table 5.2: Segment 1: Basic Life Science Research Utilizing RNAi Tools and Technologies73

Table 5.3: Segment 2: RNAi for Drug Discovery and Development74

Table 5.4: Segment 3: RNAi Research for Development of RNAi Therapeutics74

Table 5.5: Segment 4: RNAi Fee-for-Service Business75

Table 5.6: Grants Awarded and Research Spending in miRNA Space, 2005-200875

Table 5.7: RNAi Opportunity and Market Size: Quantitative Model, 2006-200977

INDEX OF FIGURES

Figure 2.1: The miRNA Processing Pathway14

Figure 2.2: Growth of Scientific Publications Addressing miRNAs, 2001-200815

Figure 2.3: Mechanisms of Small RNA-induced Gene Regulation16

Figure 2.4: Types of RNAi Compounds18

Figure 2.5: Breakdown of Scientific Publications Related to RNAi by Geographic Region, 2007-200819

Figure 3.1: End-User Segmentation of RNAi Space27

Figure 3.2: RNAi Patents Filed Globally, by Geographical Origin39

Figure 3.3: Selected Deals in RNAi Space42

Figure 4.1: Geographical Breakdown of RNAi End-User Survey Respondents55

Figure 4.2: Affiliation of RNAi End-User Survey Respondents55

Figure 4.3: Utilization of RNAi Technologies/Products by Respondent Pool56

Figure 4.4: RNAi Utilization Period: Breakdown of Respondent Pool56

Figure 4.5: Research Applications Using RNAi Technologies/Products57

Figure 4.6: Types of RNAi Technologies Currently Utilized58

Figure 4.7: RNAi Technologies Most Commonly Utilized Currently by End-Users58

Figure 4.8: Types of RNAi Technologies: Expected Use in Six to 18 Months59

Figure 4.9: Evolution of Market Shares of RNAi-Inducing Technologies60

Figure 4.10: Number of Experiments Involving RNAi Conducted per Week60

Figure 4.11: Range of Research Dollars Spent Monthly on RNAi Research61

Figure 4.12: RNAi Experiment Throughput Correlated with Type of RNAi Technology Used62

Figure 4.13: Current RNAi Market Share by Segments63

Figure 4.14: Growth/Decline Rate of RNAi Marketplace Segments (Six to 18 Months)64

Figure 4.15: Product Formats Utilization for RNAi Research (Current and Six to 18 Months)65

Figure 4.16: Companies Offering Product Formats for Currently Used RNAi Products67

Figure 4.17: RNAi Product Offerings/Formats Use (Projections-Six to 18 Months)68

Figure 4.18: Percentage Change of RNAi Product Offerings/Formats (Six to 18 Months)69

Figure 4.19: Key Challenges Faced by End-Users in RNAi Space70

Figure 4.20: Unmet Needs in RNAi Space Ranked by Importance to End-Users71

Figure 5.1: Growth and Evolution of miRNA Space76

Figure 5.2: Elements of RNAi Value Chain77

Figure 5.3: Growth and Evolution of RNAi (siRNA/shRNA) Space78

Figure 5.4: Market Revenues Based on Components of siRNA Experimental Paradigm80

 

Other users found this report page using the following search terms: RNAi RNAsi disadvantage small rnai interference rna advantage types growth mirna publications

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.